2cureX AB (publ) (2CUREX.ST)
SEK 0.35
(0.86%)
SEK 0.35
(0.86%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -35.13 Million SEK | -26.19% |
| 2022 | -29.45 Million SEK | -33.77% |
| 2021 | -22.44 Million SEK | -176.48% |
| 2020 | -7.03 Million SEK | 4.19% |
| 2019 | -8.31 Million SEK | -3.85% |
| 2018 | -8 Million SEK | -119.13% |
| 2017 | -3.65 Million SEK | -177.41% |
| 2016 | -1.31 Million SEK | -85.33% |
| 2015 | -731.5 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.75 Million SEK | 49.88% |
| 2024 Q2 | -4.75 Million SEK | 0.0% |
| 2023 Q2 | -8.58 Million SEK | -2.47% |
| 2023 FY | - SEK | -26.19% |
| 2023 Q4 | -8.85 Million SEK | 3.47% |
| 2023 Q3 | -9.17 Million SEK | -6.88% |
| 2023 Q1 | -8.37 Million SEK | -80.22% |
| 2022 Q2 | -7.47 Million SEK | 6.75% |
| 2022 FY | - SEK | -33.77% |
| 2022 Q4 | -4.64 Million SEK | 50.19% |
| 2022 Q3 | -9.32 Million SEK | -24.84% |
| 2022 Q1 | -8.01 Million SEK | -17.6% |
| 2021 Q3 | -6.46 Million SEK | -3.94% |
| 2021 Q2 | -6.22 Million SEK | -146.53% |
| 2021 Q1 | -2.52 Million SEK | -10.22% |
| 2021 FY | - SEK | -176.48% |
| 2021 Q4 | -6.81 Million SEK | -5.4% |
| 2020 Q3 | -1 Million SEK | 53.89% |
| 2020 Q2 | -2.18 Million SEK | 11.93% |
| 2020 FY | - SEK | 4.19% |
| 2020 Q4 | -2.28 Million SEK | -127.08% |
| 2020 Q1 | -2.48 Million SEK | -32.87% |
| 2019 FY | - SEK | -3.85% |
| 2019 Q1 | -1.65 Million SEK | -9.79% |
| 2019 Q3 | -1.91 Million SEK | 33.3% |
| 2019 Q4 | -1.86 Million SEK | 2.45% |
| 2019 Q2 | -2.87 Million SEK | -73.06% |
| 2018 Q1 | -2.87 Million SEK | -66.82% |
| 2018 FY | - SEK | -119.13% |
| 2018 Q3 | -607 Thousand SEK | 79.84% |
| 2018 Q2 | -3.01 Million SEK | -4.66% |
| 2018 Q4 | -1.51 Million SEK | -148.93% |
| 2017 Q4 | -1.72 Million SEK | -640.16% |
| 2017 FY | - SEK | -177.41% |
| 2017 Q1 | -1.48 Million SEK | -372.95% |
| 2017 Q2 | -1.16 Million SEK | 21.59% |
| 2017 Q3 | -233 Thousand SEK | 79.95% |
| 2016 FY | - SEK | -85.33% |
| 2016 Q4 | 542.96 Thousand SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Simris Alg AB (publ) | -22.36 Million SEK | -57.117% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 88.932% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 87.542% |
| Xintela AB (publ) | -53.47 Million SEK | 34.29% |
| Active Biotech AB (publ) | -43.88 Million SEK | 19.94% |
| Amniotics AB (publ) | -27.14 Million SEK | -29.448% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -147.141% |
| BioArctic AB (publ) | 275.38 Million SEK | 112.759% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 90.447% |
| Camurus AB (publ) | 562.54 Million SEK | 106.246% |
| Cantargia AB (publ) | -284.31 Million SEK | 87.642% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -79.458% |
| CombiGene AB (publ) | -35.33 Million SEK | 0.566% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 75.054% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -105.66% |
| Genovis AB (publ.) | 64.57 Million SEK | 154.414% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 69.422% |
| Mendus AB (publ) | -97.84 Million SEK | 64.091% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 5.099% |
| Intervacc AB (publ) | -68.98 Million SEK | 49.063% |
| Kancera AB (publ) | -61.88 Million SEK | 43.227% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -31.188% |
| LIDDS AB (publ) | -39.67 Million SEK | 11.429% |
| Lipum AB (publ) | -37.11 Million SEK | 5.342% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -190.284% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 211.884% |
| NextCell Pharma AB | -40.98 Million SEK | 14.271% |
| OncoZenge AB (publ) | 7.26 Million SEK | 583.567% |
| Saniona AB (publ) | -69.69 Million SEK | 49.586% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 79.309% |
| Ziccum AB (publ) | -20.34 Million SEK | -72.726% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 1756900.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 85.213% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -1589.231% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -161.604% |
| Corline Biomedical AB | -1.69 Million SEK | -1977.824% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 79.728% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 35.89% |
| Aptahem AB (publ) | -10 Million SEK | -251.036% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 404.234% |
| Fluicell AB (publ) | -25.91 Million SEK | -35.587% |
| Biovica International AB (publ) | -119.5 Million SEK | 70.599% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 16.787% |
| AcouSort AB (publ) | -16.7 Million SEK | -110.357% |
| Abliva AB (publ) | -93.6 Million SEK | 62.465% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 88.989% |
| I-Tech AB | 30.34 Million SEK | 215.788% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 95.083% |
| Cyxone AB (publ) | -20.41 Million SEK | -72.117% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 65.705% |
| Biosergen AB | 228 Thousand SEK | 15510.526% |
| Nanologica AB (publ) | -62.11 Million SEK | 43.438% |
| SynAct Pharma AB | -222.7 Million SEK | 84.223% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 19.892% |
| BioInvent International AB (publ) | -312.7 Million SEK | 88.764% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 11455.696% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 83759.135% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 84.83% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -298.707% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 67.634% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -206.356% |